Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Therma Bright Inc V.THRM

Alternate Symbol(s):  TBRIF

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.


TSXV:THRM - Post by User

Comment by InvrsContrarianon Sep 26, 2021 4:07pm
162 Views
Post# 33921110

RE:RE:RE:FDA EUA Speed of Review in 1st 9 month…

RE:RE:RE:FDA EUA Speed of Review in 1st 9 month… This begs the question :what companies are better positioned to take advantage of your research. My best guess would be the ones that have more use cases already or about to be approved. Just further along the queue.
Watchman21 wrote:

@TheeRook.  Thanks for the updated data.  Great find.  And 440 within 18 month at an average of 20.5 workdays per month ... breaks down to 440 test variations / 369 workdays = averages 1.2 test variations per workday.  Still a rapid pace from March 2020 through Sept 2021 (18 months later) 

Now why do I say 440 test variations versus 440 unique tests.  Re-check the 34 Antigen tests.  If you copy and paste the chart into an excel spreadsheet and sort by company you will clearly see it's 20 unique companies with 20 unique tests that have 34 use procedure variations.  

Note, I 've read each one of the FDA-EUA for each of tge 34 antigen test submissions, also discovered when some were first submitted and when their first got approved.  I'm still here.  

Abbott alone has 1 test that has about 6 submissions of this same test for various purposes. (1) point of care, (2) at home with health care proctor, (3) at home with digital mobile app, (4) submission for updated requirements, 5) at home / self test (personal use) , etc...  

So technically only 20 antigen tests have been approved... and these 20 companies continue to submit their same tests to secure FDA EUA apprival around various test procedures.

20 antigen tests for 34 use cases is really a small number when looking at the other test categories that take lab work, highly priced machinery and lab technicians make $10-20/ per hour.  


These 20 antigen, and I suspect 21 soon (TB),are the most affordable and have the most marketshare opportunit than PCR and Antiboody tests going forward.  And they are easier, quicker and again more affordable  for the end user... the general public consumer.  -and saliva is so much easier and comfortable than a swab up your nose.

25% of US won't get vacinnated, probably higher now children will get thrown in.   So 25% of 330m is 84.5 people who will be asked to tests frequently to participate in life... that's 4.2m per 21 tests.  At $10 per test multiple times per week, that's a lot of $$$ and a spit test will be so much better than nasal.  Plus all the vacs people who get sick but not deathly, will test for Covid19 variants.  And that's just the USA.  

(Sure the PCR and Antibody list probably are similar with same tests being resubmitted,, but not as many use case processes, as most require lab work and running the test through machines.  All take time.)

it's easy to copy, paste and sort and see this is how it's  playing out.   I predict Therma's Acuvid Covid 19 Rapid Antigen Saliva Test will have multiple submissions over time..  point of care, at home with afero's digital connect, at-home/self test w/ afero, updates for compliance, etc


https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2
 

My Sunday morning reading & response as I drink my coffee.  And wait for the family to wake... 



<< Previous
Bullboard Posts
Next >>